STOCK TITAN
  1. Home
  2. News
  3. TRVI

Trevi Therapeutics (TRVI) Stock News

TRVI Nasdaq

Welcome to our dedicated page for Trevi Therapeutics news (Ticker: TRVI), a resource for investors and traders seeking the latest updates and insights on Trevi Therapeutics stock.

Trevi Therapeutics, Inc. reports news on its clinical-stage biopharmaceutical development of Haduvio, an oral extended-release formulation of nalbuphine, for chronic cough in patients with idiopathic pulmonary fibrosis, non-IPF interstitial lung disease, and refractory chronic cough. Company updates commonly cover clinical trial results and plans, FDA interactions, medical-conference presentations, intellectual property, and the investigational status of Haduvio.

Trevi also reports financing and corporate updates tied to its development strategy, including common stock offerings, quarterly financial results, cash runway commentary, and participation in healthcare investor events.

News

Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

Rhea-AI Summary
Trevi Therapeutics (NASDAQ: TRVI) has successfully closed its previously announced underwritten public offering, raising approximately $115.1 million before expenses. The offering included 20,010,000 shares of common stock priced at $5.75 per share, with underwriters fully exercising their option to purchase an additional 2,610,000 shares. The biopharmaceutical company, which is developing Haduvio (oral nalbuphine ER) for chronic cough treatment in IPF and RCC patients, conducted the offering through joint book-running managers Morgan Stanley, Leerink Partners, Stifel, and Cantor. The offering was made pursuant to a shelf registration statement on Form S-3 filed with the SEC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.75%
Tags
none
-
News

Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock

Rhea-AI Summary
Trevi Therapeutics (NASDAQ: TRVI) has announced the pricing of an underwritten public offering of 17.4 million shares of common stock at $5.75 per share, aiming to raise $100 million before deducting underwriting costs. The company, which is developing Haduvio for chronic cough in IPF and RCC patients, has also granted underwriters a 30-day option to purchase up to 2.61 million additional shares. The offering is expected to close around June 5, 2025, with Morgan Stanley, Leerink Partners, Stifel, and Cantor serving as joint book-running managers. The shares are being offered through a shelf registration statement on Form S-3 that was declared effective by the SEC on August 15, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.59%
Tags
offering
-
News

Trevi Therapeutics Announces Proposed Public Offering of Common Stock

Rhea-AI Summary
Trevi Therapeutics (NASDAQ: TRVI) has announced a proposed public offering of $100 million worth of common stock shares, with an additional 30-day option for underwriters to purchase up to $15 million more shares. The clinical-stage biopharmaceutical company, which is developing Haduvio (oral nalbuphine ER) for chronic cough treatment in IPF and RCC patients, will offer all shares through joint book-running managers Morgan Stanley, Leerink Partners, Stifel, and Cantor. The offering will be conducted under a previously filed shelf registration statement that was declared effective by the SEC on August 15, 2023. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.78%
Tags
offering
News

Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough

Rhea-AI Summary
Trevi Therapeutics (NASDAQ: TRVI) announced positive Phase 2b CORAL trial results for Haduvio in treating chronic cough in idiopathic pulmonary fibrosis (IPF) patients. The trial met its primary endpoint with significant reductions in 24-hour cough frequency across all dose groups, with the highest dose (108mg BID) achieving a -43.3% placebo-adjusted reduction. The drug demonstrated rapid efficacy at Week 2 and was well-tolerated, with similar discontinuation rates between treatment (5.6%) and placebo (5.0%) groups. Secondary endpoints showed significant improvements in cough severity and patient-reported outcomes. The company plans to meet with the FDA and initiate Phase 3 trials in first half of 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3%
Tags
clinical trial
-
News

Trevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough

Rhea-AI Summary
Trevi Therapeutics (NASDAQ: TRVI) has scheduled a conference call and webcast for June 2nd, 2025, at 8:30 a.m. ET to present topline results from their Phase 2b CORAL trial. The trial evaluates Haduvio (oral nalbuphine ER) for treating chronic cough in patients with idiopathic pulmonary fibrosis (IPF). The presentation will be accessible via webcast with audio and slides, and participants can join by phone at (877) 870 4263 (domestic) or (412) 317 0790 (international). A 30-day replay will be available on the company's website after the event. Haduvio is also being investigated for refractory chronic cough (RCC) treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3%
Tags
conferences clinical trial
-
News

Trevi Therapeutics to Participate in Upcoming June Conferences

Rhea-AI Summary

Trevi Therapeutics (NASDAQ: TRVI), a clinical-stage biopharmaceutical company developing Haduvio™ (oral nalbuphine ER) for chronic cough treatments, announced its participation in three major conferences in June 2025. The company will present at the American Cough Conference (June 6-7) discussing RIVER trial demographics for refractory chronic cough. At the CPDD 87th Annual Scientific Meeting (June 14-18), they will present research on nalbuphine's human abuse potential. Finally, at the BIO International Convention (June 16-19), the company will deliver a corporate presentation. Key executives, including CEO Jennifer Good and other senior management, will represent Trevi at these events.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.6%
Tags
conferences
News

Trevi Therapeutics Announces Additional Analyses from Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

Rhea-AI Summary
Trevi Therapeutics (NASDAQ: TRVI) has presented additional analyses from its Phase 2a RIVER trial of Haduvio™ (oral nalbuphine ER) for refractory chronic cough (RCC). The trial met its primary endpoint with a 67% reduction in 24-hour cough frequency from baseline and 57% on a placebo-adjusted basis (p0.0001)
  • Statistically significant responder analyses across all doses at 30%, 50%, and 75% thresholds
  • Significant improvement in Leicester Cough Questionnaire at Day 21
  • Adverse events were more common during initial exposure (27mg BID) but decreased over time
  • Most discontinuations occurred in first two weeks due to CNS and GI-related adverse events
    • The company awaits Phase 2b trial results in IPF patients with chronic cough to determine future development strategy.
    Rhea-AI Impact
    Rhea-AI Sentiment
    End-of-Day
    -0.31%
    Tags
    clinical trial
    -
    News

    Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

    Rhea-AI Summary
    Trevi Therapeutics (NASDAQ: TRVI) reported Q1 2025 financial results and key developments for its drug candidate Haduvio. The company announced positive Phase 2a RIVER trial results showing a significant 67% reduction in 24-hour cough frequency from baseline in refractory chronic cough patients. The Phase 2b CORAL trial for IPF patients with chronic cough completed enrollment and last patient visit, with topline results expected in Q2 2025. Financially, Trevi ended Q1 with $103.3 million in cash, providing runway into Q4 2026. The company reported R&D expenses of $7.8 million (down from $8.8 million in Q1 2024) and G&A expenses of $3.7 million (up from $3.1 million), resulting in a net loss of $10.3 million compared to $10.9 million in the same period last year.
    Rhea-AI Impact
    Rhea-AI Sentiment
    End-of-Day
    -- %
    Tags
    earnings
    -
    News

    Trevi Therapeutics to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 8, 2025

    Rhea-AI Summary

    Trevi Therapeutics (NASDAQ: TRVI) has scheduled its Q1 2025 financial results and corporate update conference call for May 8, 2025, at 4:30 p.m. ET. The company, which is developing Haduvio™ (oral nalbuphine ER) for chronic cough treatment in patients with idiopathic pulmonary fibrosis (IPF) or refractory chronic cough (RCC), will host the event via conference call and live audio webcast. Investors can join by dialing (877) 870 4263 (domestic) or (412) 317 0790 (international). The webcast will be available through the 'Investors & News' section on Trevi's website and archived for 30 days afterward.

    Rhea-AI Impact
    Rhea-AI Sentiment
    End-of-Day
    1.3%
    Tags
    conferences earnings
    News

    Trevi Therapeutics to Participate in Upcoming April Investor Conferences

    Rhea-AI Summary

    Trevi Therapeutics (Nasdaq: TRVI), developing Haduvio™ (oral nalbuphine ER) for chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), has announced its participation in three major investor conferences this April 2025.

    The company will present at the following events:

    • 24th Annual Needham Virtual Healthcare Conference (April 7-10) with a corporate presentation on April 7 at 11:00-11:40 a.m. ET
    • Jones Healthcare and Technology Innovation Conference (April 8-9) in Las Vegas, with a presentation on April 9 at 11:00-11:20 a.m. PT
    • Piper Sandler Spring Biopharma Symposium (April 16-17) in Boston

    Rhea-AI Impact
    Rhea-AI Sentiment
    End-of-Day
    -0.96%
    Tags
    conferences

    FAQ

    What is the current stock price of Trevi Therapeutics (TRVI)?

    The current stock price of Trevi Therapeutics (TRVI) is $18.75 as of August 4, 2026.

    What is the market cap of Trevi Therapeutics (TRVI)?

    The market cap of Trevi Therapeutics (TRVI) is approximately 2.5B.